Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Evan Y. Yu, MD
Fred Hutch/University of Washington Cancer Consortium
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Johns Hopkins University
Baltimore, Maryland, United States
Ana Kiess, MDRecruiting - Bozeman Health Deaconess Hospital
Bozeman, Montana, United States
Active, not recruiting - Fred Hutch/university of Washington Cancer Consortium
Seattle, Washington, United States
Evan Y. Yu, MDRecruiting - University of Wisconsin-Madison
Madison, Wisconsin, United States
Glenn Liu, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Apr 2021
- Primary completion
- 1 Aug 2026
- Completion
- 1 Aug 2029
- Last update posted
- 17 Feb 2026
- Registered enrollment
- 48
- Registry id
- NCT04489719
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.